Company Encyclopedia
View More
name
Theriva Biologics
TOVX.US
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics.
1.902 T
TOVX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Theriva Biologics Advances Oncology Pipeline with VCN-01

    Theriva Biologics, Inc. (TOVX) reported advancements in its oncology pipeline, particularly with VCN-01, which showed promising results in a Phase 2b trial for metastatic pancreatic ductal adenocarcinoma (PDAC). The company improved its cash position to $15.5 million and plans to advance regulatory discussions for VCN-01 and VCN-12. General and administrative expenses decreased to $1.9 million, while research and development expenses slightly fell to $2.6 million. Theriva aims to leverage its financial position for further clinical development and potential partnerships, focusing on regulatory milestones and expanding its oncology pipeline.

    Tip Ranks·
    US
    TOVX
    -6.58%
    Tip Ranks·
    US
    TOVX
    -6.58%

    Theriva Biologics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    TOVX
    -6.58%
    LB filings·
    US
    TOVX
    -6.58%

    Theriva Biologics | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    TOVX
    -6.58%
    LB filings·
    US
    TOVX
    -6.58%

    Theriva Biologics Inc. Announces Date for Upcoming Special Stockholders Meeting

    Theriva Biologics Inc. will hold a Special Meeting of Stockholders on December 15, 2025, at its principal office in Rockville, Maryland. This announcement was published via EDGAR by the U.S. Securities and Exchange Commission on October 31, 2025. The content is generated by Public Technologies and is for informational purposes only, not to be interpreted as financial, investment, or legal advice.

    Reuters·
    US
    TOVX
    -6.58%
    Reuters·
    US
    TOVX
    -6.58%

    Theriva Biologics Files Prospectus for Stock Offering

    Theriva Biologics has filed a prospectus supplement for a stock offering totaling $4,019,597. The offering will involve the sale of common stock through A.G.P./Alliance Global Partners, with the sales agent receiving up to a 3% commission. This stock sale is classified as an "at the market offering" under SEC rules, as per the original SEC filing dated October 24, 2025.

    TradingView·
    US
    TOVX
    -6.58%
    TradingView·
    US
    TOVX
    -6.58%
    © 2025 Longbridge｜Disclaimer